Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pharmaceutical industry

Drug and medical device companies paid US doctors and hospitals US$6.5bn in 2014

Pharmaceutical and medical device companies made US$6.49bn in fees, according to figures published as part of the Open Payments programme, brought about by the US Affordable Care Act 2010. In the image, Barack Obama signs the Act

Source: Pete Souza / Wikimedia Commons

The Open Payments programme was created under the reforms brought about by the US Affordable Care Act 2010

Pharmaceutical and medical device companies paid US$6.5bn in fees to US physicians and teaching hospitals in 2014, according to statistics collated by the Centers for Medicare and Medicaid Services (CMS) in the United States. 

The fees for either participating in drug studies or for more general support including consultancy, event speaking and travel and entertainment costs were made by 1,444 different companies, reveal figures published as part of the Open Payments programme on 30 June 2015. 

Research payments totalled US$3.2bn, while general payments made up US$2.6bn of the bill. The US$703m balance in fees fell under industry ownership and investment interests held by physicians or their immediate family. 

The CMS-held database revealed that fees were paid to 1,121 teaching hospitals and 607,000 physicians who had payment records. There were around 11.4 million transactions between industry and trusts and physicians in 2014. 

The Open Payments programme was created under the reforms brought about by the US Affordable Care Act 2010 — commonly known as ‘Obamacare’ — which aims to give consumers more control over their health insurance. The programme, facilitated by CMS, is a searchable and public database of payments, honoraria or research grants paid by global drug and drug device manufacturers to individual US physicians or teaching hospitals. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068937

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Pharmaceutical and medical device companies made US$6.49bn in fees, according to figures published as part of the Open Payments programme, brought about by the US Affordable Care Act 2010. In the image, Barack Obama signs the Act

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.